Early cancer drug trial halted before full testing

NCT ID NCT05252390

Terminated Disease control Sponsor: Nuvation Bio Inc. Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested a new oral drug called NUV-868, both alone and combined with two existing cancer medications (olaparib or enzalutamide), in adults with advanced solid tumors. The goal was to find safe doses and see if these treatments could help control cancers like ovarian, pancreatic, prostate, and triple-negative breast cancer that had stopped responding to other therapies. The study was stopped by the sponsor before the main effectiveness testing phase could begin.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Cabrini Hospital Malvern

Malvern, Victoria, 3144, Australia
Calvary Mater Hospital Newcastle

Waratah, New South Wales, 2298, Australia
Carolina BioOncology Institute

Huntersville, North Carolina, 28078, United States
Ellison Institute of Technology

Los Angeles, California, 90064, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19104, United States
H. Lee Moffitt Cancer Center

Tampa, Florida, 33612, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Laura & Isaac Perlmutter Cancer Center - NYU Langone Health

New York, New York, 10016, United States
Linear Clinical Research

Nedlands, Western Australia, 6009, Australia
Macquarie University Hospital

North Ryde, New South Wales, 2109, Australia
Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
NEXT Virginia

Fairfax, Virginia, 22031, United States
Peter Maccallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Rocky Mountain Cancer Centers, LLP

Aurora, Colorado, 80012, United States
Rocky Mountain Cancer Centers, LLP

Lone Tree, Colorado, 80124, United States
Sarah Cannon Research Institute - Tennessee Oncology

Nashville, Tennessee, 37203, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21231, United States
Texas Oncology - Fort Worth Cancer Center

Fort Worth, Texas, 76104, United States
The University of Arizona Cancer Center

Tucson, Arizona, 85724, United States
Virginia Oncology Associates

Norfolk, Virginia, 23502, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR BREAST CANCER BREAST CARCINOMA BREAST TUMOR CANCER OF BREAST CANCER OF OVARY CANCER OF PANCREAS CANCER OF PROSTATE CANCER OF THE BREAST CANCER OF THE OVARY CANCER OF THE PANCREAS CANCER OF THE PROSTATE CASTRATE RESISTANT PROSTATE CANCER CASTRATION RESISTANT PROSTATIC NEOPLASMS CASTRATION-RESISTANT PROSTATIC CANCER OVARIAN CANCER OVARY CANCER OVARY NEOPLASM PANCREAS CANCER PANCREAS NEOPLASM PANCREATIC CANCER PROSTATE CANCER PROSTATE NEOPLASM PROSTATIC CANCER TRIPLE NEGATIVE BREAST NEOPLASMS TRIPLE-NEGATIVE BREAST CANCER